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Erythropoietin enhances vascular responsiveness to
norepinephrine in renal failure
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and DAVID J. WEBB
The Universily of Edinburgh, Department of Medicine, Western General Hospital, Edinburgh, Scotland, United Kingdom
Erythropoietin enhances vascular responsiveness to norepinephrine in
renal failure. The mechanism of hypertension induced by recombinant
human erythropoietin (rHuEPO) is unclear but may include an increase in
peripheral vascular resistance. We studied changes of arterial pressure
and plasma endothelin in nine consecutive hemodialysis patients before,
and 6 and 12 weeks after, starting rHuEPO. In six patients, changes in
cardiac index (CI), stroke index (SI) and total peripheral resistance index
(TPRI) were measured by bioimpedance, and forearm vascular respon-
siveness to intra-arterial norepinephrine (30 to 240 pmol/min) and endo-
thelin-1 (5 pmol/min) were assessed. Six healthy age and sex matched
subjects also underwent assessment of forearm vascular responsiveness to
norepinephrine and endothelin-1. Treatment with rHuEPO significantly
increased hemoglobin and mean arterial pressure (MAP). TPRI also
increased by 35 11%. Plasma endothelin, although elevated basally,
remained unchanged. Intra-arterial infusion of norepinephrine caused a
maximal increase in forearm vascular resistance (FVR) of 17 9%before
rHuEPO, significantly less than the 32 5% increase in healthy control
subjects (P = 0.04). The response increased to 65 15% (P = 0.03) after
12 weeks rHuEPO treatment (P = 0.51 vs. controls). Endothelin-1 caused
a maximal increase of FVR at 60 minutes of 45 24% before rHuEPO,
which was not significantly different from controls, and tended to decrease
with rHuEPO therapy. The response to endothelin-1, but not norepineph-
rifle, correlated inversely with MAP (r =
—0.52; P = 0.03) and TPRI (r =
—0.51; P = 0.04). In conclusion, these studies show that anemia in chronic
renal failure is associated with depressed vascular responsiveness to
norepinephrine which is restored by rHuEPO therapy. In contrast,
vascular responses to endothelin-1 tend to reduce with rHuEPO therapy.
The change in vascular responsiveness to norepinephrine may contribute
to the increase in arterial pressure associated with rHuEPO therapy.
Recombinant human eiythropoietin (rHuEPO) corrects the
anemia of chronic renal failure [1, 21. It is recognized, however,
that rHuEPO may increase arterial pressure in previously normo-
tensive subjects, or exacerbate pre-existing hypertension [31. Al-
though the mechanism for this hypertension is unknown, it is
likely to be multifactorial [I.
Hypertension following rHuEPO is associated with an increase
in peripheral vascular resistance [5] and may be exacerbated by
failure of an elevated cardiac output to decrease in response to
increases in hemoglobin [6, 7]. Although increases of hematocrit
and viscosity secondary to rHuEPO therapy may contribute to the
rise in vascular resistance [8], and although the development of
hypertension may occur in parallel with the increase in hemato-
crit, one fifth of individuals who become hypertensive do so some
months after the hematocrit has stabilized at its new higher level
[61. Also, studies in animals suggest that when the hematocrit is
increased to a similar extent with rHuEPO or transfusion, arterial
pressure increases in the rHuEPO, but not the transfused, group
[91. In addition, although increasing the hematocrit in humans
from 20 to 40% by transfusion increases arterial pressure [101,
hypertension does not appear to occur when the hematocrit is
increased only to 30% [11]. Furthermore, several studies have
failed to find a relationship between changes in arterial pressure
and changes in hematocrit or viscosity [4, 6, 121. Finally, although
rHuEPO increases whole blood viscosity, peripheral vascular
resistance increases to a much greater extent than would be
predicted from this effect [131.
Increased circulating concentrations of vasoactive hormones
may contribute to the increase in arterial pressure in patients
treated with rHuEPO [14]. However, reports of the effects of
rHuEPO have been conflicting: renin activity and atrial natriuretic
peptide concentrations do not change [11, 14, 15] or decrease
[16—18], and changes in the renin-angiotensin system appear to be
secondary to alterations in red cell mass and plasma volume [19].
Norepinephrine concentrations may increase [20], decrease [13]
or, like epinephrine and dopamine, remain unchanged [111.
Plasma concentrations of the locally active hormone endothelin-1
have been reported as unchanged [15] or increased [12, 17, 21] in
response to treatment with rHuEPO.
Although animal studies and in vitro studies in humans have
been undertaken, it is not known whether in vivo vascular
reactivity to norepinephrine or endothelin-1 is altered in patients
with chronic renal failure receiving rHuEPO. Hence, we have
investigated the effect of treatment with rHuEPO on systemic
hemodynamics and responsiveness of the forearm resistance
vessels to local doses of norepinephrine and endothelin-1 given
via the brachial artery.
Methods
Subjects
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We studied nine consecutive patients (5 men, 4 women; 24 to 67
years) with established end-stage renal disease (Table 1), who had
been maintained on hemodialysis given three times each week for
at least three months before starting rHuEPO. Subjects had all
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Table 1. Patient characteristics
Patient Diagnosis Age Sex
Antihypertensive
medication Ranitidine
Iron
sulphate
Phosphate
binders
1-Alpha
calcidol NSAIDs
1 Obstructive uropathy 67 M None — + + + +
2 Chronic pyelonephritis 39 F None — — — —
3 Chronic pyelonephritis 34 M None — + + + —
4 Bilateral nephrectomy 59 F None — + + + —
5 Mesangiocapillaiy glomerulonephritis 32 M Enalapril, Nifedipine SR + — + + —
6 Focal necrotizing glomerulonephritis 26 F None — — + +
7 Chronic pyelonephritis 58 F None + + — + —
8 Crescentic glomerulonephritis 42 M Nifedipine SR + + — — +
9 Mesangiocapillaiy glomerulonephritis 32 M None + + + — +
Subjects 1—6 underwent both intra-arterial and hemodynamic studies; subjects 7—9 underwent blood pressure monitoring and blood sampling only.
Non-steroidal anti-inflammatory drugs (NSAIDs) were avoided for 1 week before each intra-arterial study. Abbreviations are: M, male; F, female; +,
drug used; —, drug not used.
maintained a stable arterial pressure for the preceding three
months, had not previously received rHuEPO, and had a stable
hemoglobin of 8 g/dl or less. All studies were conducted with the
approval of the local Ethics Review Committee and patients gave
their written informed consent to participate. Patients avoided
non-steroidal anti-inflammatory drugs for the week before, and
caffeine-containing drinks or cigarettes on the day of, each study.
In addition, patients were fasted for at least three hours before
each study.
Six subjects (3 men, 3 women; 24 to 67 years: mean age 43 5
years) completed the full study protocol. The other three subjects
(2 men, 1 woman, 32 to 58 years), because of poor vascular access,
underwent blood sampling and arterial pressure monitoring but
not intra-arterial drug infusion. All patients were self-medicating
(Table 1) and their diet was high in calories but limited to a daily
intake of 1 g/kg body wt protein, 80 to 100 mmol sodium and 1
mmol/kg body wt potassium, with a daily fluid restriction of 500 ml
plus a volume equal to the previous 24 hours urine output.
Six healthy age and sex matched subjects (4 men, 2 women; 29
to 63 years, mean age 43 5 years) were studied at a later date
to establish vascular responsiveness to norepinephrine and endo-
thelin-1 in a healthy control group. These subjects had normal
renal function (plasma creatinine 83 8 molIliter), did not
receive rHuEPO, and underwent intra-arterial drug infusion on
one occasion only.
Procedures
A 21 SWG cannula was inserted under local anesthesia using
1% lignocaine hydrochloride (Astra Pharmaceuticals Limited,
Kings Langley, UK) into a vein on the fistula arm, but not into the
fistula, for the purpose of blood sampling in the hemodialysis
patients, or into the dominant arm in controls. A 27 SWG steel
cannula (Cooper's Needle Works, Birmingham, UK) was inserted
into the brachial artery of the non-fistula arm, or non-dominant
arm in controls, under local anesthesia for the purpose of
intra-arterial infusion of drugs. Forearm blood flow was measured
only in the infused arm, using venous occlusion plethysmography
[221 adapted for use with indium-and-gallium-in-silastic strain
gauges [23]. Measurements were made for 10 seconds in every 15
seconds over a three minute period. Blood flow to the hand was
excluded during each three minute measurement period.
Arterial pressure was measured using a well-validated semi-
automated oscillometric method (Takeda UA 751 [24, 25]).
Cardiac output and stroke volume were measured using a well-
Table 2. Hematological effects of rHuEPO
Pre-
rHuEPO
6 Weeks
rHuEPO
12 Weeks
rHuEPO
Hemoglobin g/dl
Hematocrit %
Mean cellular volume ft
Platelets x109/ljter
White blood count x 109/liter
Plasma viscosity cp
7.0 0.3
20.4 0.992 2
212 30
6.4 0.8
1.59 0.05
7.8 0.6
22.8 1.894 2
219 26
5.7 0.6
1.56 0.04
9.1 0.6
26.5 1.791 2
228 25
6.3 0.6
1.58 0.04
ap < 0.02 (pre vs. 12 weeks)
validated non-invasive bioimpedance method (model NCCOM3;
BoMed Medical Manufacturer Ltd, Irvine, CA, USA) [26, 27].
Drugs
All patients received subcutaneous recombinant human eryth-
ropoietin-beta (rHuEPO; Recormon-Boehringer Mannheim UK,
Livingston, UK), three times weekly after dialysis, at a dose of 50
U/kg. Our local protocol dictated that this dose should be
adjusted to allow no more than a 4% rise of hematocrit every two
weeks. Intra-arterial norepinephrine (30, 60, 120 and 240 pmol/
mm; Sanofi Winthrop Limited, Guildford, UK), endothelin-1 (5
pmol/min; Clinalfa, Laufelfingen, Switzerland) and physiologic
saline (0.9%; Baxter Healthcare Limited, Thetford, UK) were
administered at locally but not systemically active doses via the
brachial artery cannula. The dose of endothelin-1 was based on
previous work showing that it produced progressive vasoconstric-
tion, with a maximum reduction in forearm blood flow of —40%
after 60 minutes [23]. The doses of norepinephrine were based on
previous studies [28], and intended to cause a similar reduction in
local blood flow. Vasoconstriction to endothelin-1 is sustained
whereas that to norepinephrine is short-lasting. Therefore, it was
necessary to give norepinephrine first rather than randomize the
order of infusions. All solutions were made up in physiologic
saline containing 100 g/ml ascorbic acid (Evans Medical Ltd,
Dunstable, UK) to avoid oxidation. The total rate of intra-arterial
infusion was kept constant at 1 ml/min.
Design
Studies were performed before, and at 6 and 12 weeks after,
starting rHuEPO therapy, on a mid-week non-dialysis day in a
quiet room maintained at a constant temperature of between 25
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Table 3. Hemodynamic effects of rHuEPO
Pre-
rHuEPO
6 Weeks
rHuEPO
12 Weeks
rHuEPO Control
Basal FBF before norepinephrine ml/100 mI/mm 3.2 0.5 3.6 0.7 3.5 0.5 2.6 0.3
Basal FVR before norepinephrineAU 35 5 34 7 32 6 32 5
FBF before endothelin-1 ml/100 mI/mm 4.5 0.5 3.0 0.6 3.6 0.5 3.2 0.3'
FVR before endothelin-1 AU 26 5 43 5° 36 9 27 2
Baseline systolic pressure mm Hg 120 12 130 13" 131 12° 121 5
Baseline diastolic pressure mm Hg 66 5 77 7 77 5° 69 3
Baseline mean arterial pressure mm Hg
Total peripheral resistance index dyn/mmn/cm5/m2
84 724 5 95 9"32 7' 95 7C29 6 86 3
Cardiac index liter/mm/rn2 3.8 0.3 3.3 0.3k' 3.8 0.7
Stroke index mI/rn2 48 5 45 3 52 9
Heart rate beats/mm 81 3 76 4 73 3 62 3C
Abbreviations are: FBF, forearm blood flow; FVR, forearm vascular resistance.
°P = 0.03 (compared to basal FVR before norepinephrine)
hP = 0.06, ° P 0.05, d P  0.01: all versus pre-rHuEPO, P 0.04 versus pre, 6 weeks and 12 weeks rHuEPO
and 28°C. The time and day of each study was the same for each
patient.
Subjects initially rested supine for 30 minutes after which, in the
patients only, cardiac output and stroke volume were measured.
Brachial artery and venous cannulation were then performed.
Saline was infused via the brachial artery cannula for 30 minutes,
after which blood was withdrawn from the venous cannula to
measure plasma endothelin-1, plasma renin activity, and serum
sodium, potassium, urea, creatinine, calcium, albumin and phos-
phate. Hemoglobin, hematocrit, platelet count, white blood count
and plasma viscosity were also measured. Norepinephrine was
then infused at incremental doses, each dose for 10 minutes, via
the brachial artery cannula, after which saline was infused for 20
minutes to allow washout of vasoconstriction to norepinephrine,
and was followed by infusion of endothelin-1 for one hour.
Forearm blood flow was recorded at 10 minute intervals during
infusion of saline and endothelin-1, and at the end of each
10-minute incremental infusion of norepinephrine. The mean of
the final five measurements of each recording period was used for
analysis. Studies were performed in a similar way in the control
subjects, although venous blood was sampled only to measure
creatinine and hemoglobin concentrations. Arterial pressure was
measured in the infused arm immediately after each blood flow
recording.
Analytical
Venous plasma samples for radioimmunoassay of endothelin-1
and renin were separated within 10 minutes and stored at —20°C.
Plasma electrolytes, hemoglobin, platelet count and plasma vis-
cosity were assayed immediately after each study. Plasma bio-
chemistry was measured using a Kodak Ectachem System E700
XRC analyzer (Kodak Diagnostics Ltd, UK) in the Department of
Clinical Chemistry, Western General Hospital, Edinburgh. Full
blood count and plasma viscosity were measured in the Depart-
ment of Hematology, Western General Hospital, Edinburgh,
using a Coulter STKS analyzer (Coulter Electronics Ltd, UK) and
a Luckhams viscometer (Denley, UK), respectively.
Plasma immunoreactive endothelin was measured using an
established method [29] with a previously validated assay [30].
The recovery of added endothelin-1 was 84%. The sensitivity of
the assay was 2 pg/mI endothelin and the mean intra- and
inter-assay coefficient of variations in our laboratory are 2.4% and
4.2%, respectively. Cross reactivity of the assay with endothelin-1,
endothelin-2, endothelin-3 and proendothelin-1 was 100%, 52%,
96% and 7%, respectively. Plasma renin activity was measured
using a commercially available radioimmunoassay method
(RIANEN, Europath Ltd, Cornwall, UK). The minimal detect-
able activity was 0.3 ng/ml/hr and the mean intra- and inter-assay
coefficient of variations in our laboratory was 12.5%.
Data presentation and statistics
Mean arterial pressure was calculated as diastolic arterial
pressure + pulse pressure. Forearm blood flow was calculated
in ml/100 ml of forearm tissue/mm. Changes in forearm blood
flow are expressed as the percentage change in blood flow at a
particular timepoint from the basal recording. Forearm vascular
resistance was calculated as mean arterial pressure divided by
forearm blood flow. Data for cardiac output and stroke volume
were corrected for body surface area, calculated according to a
standard nomogram, to provide measures of cardiac (CI) and
stroke index (SI) and are expressed as liter/min/m2 and ml/m2,
respectively. Total peripheral resistance index (TPRI) was calcu-
lated as mean arterial pressure divided by cardiac index, and
expressed as dyne/min/cm5/m2.
All results are expressed as mean SEM. The maximal response
to the norepinephrine and endothelin-1 infusions, as well as
biochemical, hematological and hemodynamic data, were ana-
lyzed by Student's paired f-test and by simple regression analysis,
as appropriate. Dose-response relationships were compared using
analysis of variance (ANOVA). The relationships between per-
centage change in responsiveness of forearm blood flow and
vascular resistance to norepinephrine and endothelin associated
with rHuEPO, and the percentage change in blood pressure,
peripheral resistance and hemoglobin with this treatment were
also examined. Comparisons between control subjects and pa-
tients for dose-response relationships were examined by analysis
of variance (ANOVA) whereas other comparisons with controls
were analyzed using Student's unpaired f-test. Statistical analysis
was performed using the STATVIEW 5l2+TM software (Brain-
power Inc., Calabasas, CA, USA) for the Apple Macintosh micro-
computer. Values of P < 0.05 were considered statistically signifi-
cant. Simple regression analysis was used primarily for hypothesis
generation and the P values accepted for statistical significance were,
therefore, not corrected for multiple comparisons.
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Results
Hematology
rHuEPO caused a progressive rise in hemoglobin and hemat-
ocrit (Table 2). In no case was it necessary to change the dose of
rHuEPO according to the requirements of our local schedule.
Two patients (patients 3 and 8) failed to have a sustained response
to rHuEPO, both as a result of iron deficiency, but also, in patient
8, because of an associated hereditary elliptocytosis. Other hema-
tological parameters, white blood count, platelet count and
plasma viscosity remained unchanged throughout the study (Ta-
ble 2). The hemoglobin of the control subjects (12.9 0.5 gldl)
was significantly higher than that of patients (P <0.001) through-
out the study (Table 2).
Arterial pressure and hemodynamics
There was a progressive increase in resting systolic, diastolic
and mean arterial pressure with rHuEPO therapy (Table 3). In
one patient (patient 5), there was a rapid increase in the diastolic
pressure from 80 to 130 mm Hg requiring aggressive medical
intervention. It was necessary to increase the dose of nifedipine to
40 mg twice daily and enalapril to 20 mg twice daily, and to add
doxazosin 2 mg three times daily and metoprolol 50 mg twice
daily, to control the arterial pressure. Over the period of the
study, resting diastolic, but not systolic or mean arterial pressure,
correlated with hemoglobin (r = 0.45;P = 0.02) and hematocrit (r
= 0.44; P = 0.02). Also, % change in hemoglobin with treatment
correlated with % change in resting systolic (r = 0.60; P = 0.05),
diastolic (r = 0.75; P = 0.008) and mean arterial (r = 0.76; P =
0.007) pressure. TPRI increased markedly and significantly (P =
0.01) after six weeks of treatment, but then decreased slightly by
12 weeks, though still tending to be higher than before treatment
(Table 3), consistent with the major effect of rHuEPO being on
peripheral vascular resistance. There was a reduction in CI at six
weeks (P = 0.05), returning to pre-treatment levels by 12 weeks,
whereas SI did not change (Table 3).
Forearm blood flow responses
There was no effect of rHuEPO on resting forearm blood flow
or vascular resistance (Table 3). In the studies performed six
weeks after starting rHuEPO, but not in the other studies,
forearm vascular resistance had not returned to basal levels (P =
0.03) after norepinephrine and before endothelin-1, and may have
tended to mask subsequent changes in forearm vascular resistance
to endothelin-1. Local infusion of norepinephrine and endothe-
lin-1 had no effect on pulse rate or arterial pressure.
Norepinephrine caused a dose-dependent reduction in forearm
blood flow. This response was increased significantly by rHuEPO.
The maximum dose of norepinephrine (240 pmol/min) reduced
blood flow by 13 4% before rHuEPO, by 44 8% (P = 0.01 vs.
pre-treatment: P = 0.07; ANOVA) at six weeks, and by 32 7%
(P = 0.07 vs. pre-treatment: P = 0.24; ANOVA) at 12 weeks of
rHuEPO therapy (Fig. 1). There was no significant relationship
between the % change in forearm blood flow with norepinephrine
(240 pmol/min) and resting systolic (r = —0.36; P 0.15),
diastolic (r =
—0.14; P = 0.59) or mean arterial pressure (r =
—0.27; P = 0.30), total peripheral resistance (r = —0.19;P = 0.45)
or hemoglobin (r = 0.03; P = 0.92). Forearm vascular resistance
increased significantly with rHuEPO in response to norepineph-
rine (240 pmol/min); by 17 9% before rHuEPO, by 123 51%
(P = 0.08 vs. pre-treatment: P = 0.07; ANOVA) at six weeks, and
by 65 15% (P = 0.03 vs. pre-treatment: P = 0.08; ANOVA) at
12 weeks of rHuEPO therapy. There was no significant relation-
ship between the % change in forearm vascular resistance with
norepinephrine (240 pmol/min) and resting systolic (r = —0.35;P = 0.17), diastolic (r = —0.24; P = 0.35) or mean arterial
pressure (r = —0.31; P = 0.23), total peripheral resistance (r =
—0.24; P = 0.35) or hemoglobin (r = —0.27; P = 0.30). There was
no significant relationship between the % change in vascular
responsiveness to norepinephrine (240 pmol/min) associated with
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Fig. 1. Effect of intra-arterial norepinephrine on forearm blood flow (A) and
forearm vascular resistance (B). Symbols are: patients before EPO therapy
(0), after six weeks of EPO (A), and after 12 weeks of EPO (•).
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rHuEPO therapy and the % change in arterial pressure, TPRI or
hemoglobin with this treatment.
The control subjects were more responsive to norepinephrine
than the patients. The maximum dose of norepinephrine (240
pmol/min) reduced blood flow by 38 5% in the controls, an
effect that was significantly greater than in patients before (P
0.01; ANOVA) but not after 6 (P = 0.70; ANOVA) or 12 weeks
(P = 0.20; ANOVA) of rHuEPO therapy. The maximum dose of
norepinephrine (240 pmol/min) increased forearm vascular resis-
tance by 32 5% in the controls, an effect that was also
significantly greater than the response in patients before (P =
0.04; ANOVA) but not after 6 (P = 0.31; ANOVA) or 12 weeks
(P = 0.51; ANOVA) of rHuEPO therapy.
Endothelin-1 caused a progressive reduction in forearm blood
flow, maximal by 60 minutes. Forearm blood flow at 60 minutes
reduced by 15 15% before rHuEPO, by 14 12% at six weeks
(P = 0.93 vs. pre-treatment: P = 0.74; ANOVA), and by 7 10%
at 12 weeks (P = 0.59 vs. pre-treatment: P = 0.42; ANOVA) (Fig.
2). The % change in forearm blood flow at 60 minutes correlated
inversely with resting systolic arterial pressure (r = —0.55; P =
0.02) and total peripheral resistance (r = —0.51; P = 0.04) but not
diastolic (r =
—0.33; P = 0.20) or mean arterial pressure (r =
—0.46; P = 0.06), or hemoglobin (r = —0.30; P = 0.25). Forearm
vascular resistance at 60 minutes increased by 45 24% before
rHuEPO, by 33 18% (P = 0.63 vs. pre-treatment: P = 0.72;
ANOVA) at six weeks, and by 20 14% at 12 weeks (P = 0.20 vs.
pre-treatment: P = 0.29; ANOVA) of rHuEPO therapy (Fig. 2).
The % change in forearm vascular resistance to endothelin-1 at 60
minutes correlated inversely with resting systolic (r =
—0.53; P =
0.03) and mean arterial pressure (r = —0.52; P = 0.03), and total
peripheral resistance (r = —0.51; P = 0.03; Fig. 3), but not with
diastolic pressure (r = —0.45; P = 0.07) or hemoglobin (r =
—0.43; P = 0.08). There was no significant relationship between
the % change in vascular responsiveness to endothelin-1 that
occurred with rHuEPO therapy, based on the 60 minute re-
sponses, and the % change in arterial pressure, TPRI or hemo-
globin.
Forearm blood flow with 60 minutes of endothelin-1 was
reduced by 23 10% in the control subjects which was not
significantly different to before (P = 0.87; ANOVA) or after 6 (P
= 0.56; ANOVA) or 12 weeks (P = 0.23; ANOVA) of rHuEPO
therapy. Forearm vascular resistance at 60 minutes was increased
by 27 2% in the control subjects which was not significantly
different to before (P = 0.92; ANOVA) or after 6 (P = 0.57;
ANOVA) or 12 weeks (P = 0.13; ANOVA) of rHuEPO therapy.
If subject 5 was excluded, on the assumption that the change in
antihypertensive medication may have influenced his results, the
maximum dose of norepinephrine reduced forearm blood flow by
10 4% before rHuEPO, by 46 10% (P = 0.007 vs. pre-
treatment: P = 0.05; ANOVA) at six weeks, and by 35 8% (P =
0.04 vs. pre-treatment: P = 0.18; ANOVA) at 12 weeks of
rHuEPO therapy. Forearm vascular resistance increased by 10
7% before rHuEPO, by 139 59% (P = 0.08 vs. pre-treatment:
P = 0.05; ANOVA) after six weeks, and by 69 18% (P = 0.02
vs. pre-treatment: P = 0.06; ANOVA) after 12 weeks of rHuEPO
therapy. After infusing endothelin-1 for 60 minutes, forearm
blood flow reduced by 26 12% before rHuEPO, by 14 15%
(P = 0.50 vs. pre-treatment: P = 0.50; ANOVA) at six weeks, and
by 3 12% (P = 0.004 vs. pre-treatment: P = 0.15; ANOVA) at
12 weeks of rHuEPO therapy. Forearm vascular resistance in-
I I I I I — —
0 10 20 30 40
Time, minutes
Fig. 2. Effect of intra-arterial endothelin-1 on forearm blood flow (A) and
forearm vascular resistance (B). Symbols are: patients before EPO therapy
(0), after six weeks of EPO (A) and after 12 weeks of EPO (U).
creased by 56 26% before rHuEPO, by 38 21% (P = 0.55 vs.
pre-treatment: P = 0.68; ANOVA) after six weeks, and by 17
17% (P = 0.02 vs. pre-treatment: P = 0.21; ANOVA) after 12
weeks of rHuEPO therapy.
Plasma endothelin and plasma renin activity
Plasma endothelin concentration, although substantially ele-
vated at 16.2 4.1 pg/mi before rHuEPO (normal as measured in
our laboratory 5.4 0.8 pg/mI) [291, did not change significantly
across the study, being 11.1 0.9 and 11.6 0.6 pg/mi at 6 and
12 weeks of treatment with rHuEPO, respectively. There was no
significant relationship between plasma endothelin concentration
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and arterial pressure or % change in vasoconstriction to endothe-
un-I or norepinephrine across the period of the study. Plasma
renin activity did not change significantly across the study; at 1.7
0.9 ng/ml/hr before rHuEPO, and 1.3 0.6 and 1.2 0.5
ng/ml/hr at 6 and 12 weeks treatment with rHuEPO, respectively.
There was no significant relationship between plasma renin
activity and changes in arterial pressure or % change in vasocon-
striction to endothelin-1 or norepinephrine across the period of
the study.
Plasma biochemistry
Apart from small changes in plasma urea and albumin concen-
trations, the measured biochemical parameters did not alter. The
number of hours of dialysis for each patient and the clinically
assessed dry weight did not change during the study. Plasma
endothelin concentrations correlated positively with creatinine (r
= 0.56; P = 0.003), urea (r = 0.51; P = 0.008) and the number of
hours dialyzed per week (r = 0.50; P = 0.01).
Discussion
In anemic hemodialysis patients with chronic renal failure
selected to start treatment with rHuEPO, we have demonstrated
an impaired responsiveness to norepinephrine which is corrected
by chronic administration of a dose of rHuEPO sufficient to cause
an increase in arterial pressure and hematocrit. In contrast, in the
same subjects, the responsiveness of forearm resistance vessels to
endothelin-1 is unaffected, or even decreased, by rHuEPO ther-
apy.
lin-1.
Our results are consistent with those of Bode-BOger et al [36],
who showed rHuEPO caused enhancement of the vascular re-
sponse to norepinephrine in rabbit aorta, and of Muller et al [13],
who found that anemia caused a disturbance of post-synaptic
alpha2-receptor function in end-stage renal disease, leading to
diminished vascular responsiveness to sympathetic stimuli that
was corrected by treatment of the anemia. In addition, Berglund
and Ekblom [37] demonstrated an increase in arterial pressure
with exercise in healthy men treated with rHuEPO, suggesting an
accentuation of the arterial pressure reaction to sympathetic
stimulation. The increase in arterial vessel responsiveness with
rHuEPO therapy to locally active doses of norepinephrine in our
study, however, contrasts with the observation of a decreased
pressor effect of systemic norepinephrine after rHuEPO therapy
[20], although this effect may occur through a central mechanism.
High plasma concentrations of norepinephrine occur in end-
stage renal disease [38], and may contribute to impaired respon-
siveness to norepinephrine because alpha2-adrenoceptor numbers
are reduced on exposure to high levels of physiological agonists.
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The increase in total peripheral resistance with rHuEPO in our
study confirms previous observations [51.Although failure of the
cardiac output to decrease with rHuEPO may contribute to
—
__ rHuEPO-associated hypertension [6, 7], the significant decrease
U in cardiac index after treatment with rHuEPO for six weeks, but
not 12 weeks, in our study suggests that the relationship may be
more complex. These results are likely to be reliable, within the
limitations of bioimpedance technology [26, 27], but need to be
confirmed using other techniques.
In contrast to previous studies demonstrating either impaired
[31, 20] or normal vascular responsiveness [32] to norepinephrine
in hemodialysis patients, our study did not use systemically active
doses of drugs that might obscure any direct vascular action by
direct effects on other organs, such as the heart and kidney, or
activate reflex mechanisms due to changes in arterial pressure. As
in our previous studies [23, 28], the lack of a systemic effect is
indicated by the absence of a change in arterial pressure or pulse
rate during infusion of either norepinephrine or endothelin-1.
Thus, our study directly and specifically examines the responsive-
ness of forearm resistance vessels in rHuEPO-treated hemodial-
ysis patients.
Changes of vascular responsiveness during rHuEPO therapy
might occur as a result of a change in vascular structure or of a
non-specific effect of treatment on the vascular smooth muscle
cells. In studies of a similar nature in patients with essential
hypertension, vascular responsiveness to norepinephrine is either
unaltered [33] or increased [34, 35] compared with healthy control
subjects, probably as a consequence of vascular structural changes
including hypertrophy [35]. In our study, correction of the im-
paired responses to norepinephrine in hemodialysis patients by
rHuEPO treatment are unlikely to be explained by vascular
structural or non-specific functional effects of rHuEPO given the
contrasting changes in response to norepinephrine and endothe-
10 15 20 25 30 35 40 45 50 55 60
Total peripheral vascular resistance index
Fig. 3. Correlation between the % increase in foreann vascular resistance
(FVR) with endothelin-1 at 60 minutes and (A) mean arterial pressure (mm
Hg) and (B) total peripheral vascular resistance index (dyn/minlcm5/m2).
Symbols are: patients before EPO therapy (0), after six weeks of EPO (A)
and after 12 weeks of EPO (U).
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Receptor down-regulation is supported indirectly through evi-
dence of impaired pressor responses to norepinephrine [31], and
more directly by reductions in platelet alpha2-receptor density and
affinity [13], in hemodialysis patients. Interestingly, there was an
inverse correlation between hemoglobin and both platelet alpha2-
receptor density and affinity in the latter study, suggesting that
renal anemia may contribute to this effect. This would certainly be
consistent with our finding of reduced responsiveness to norepi-
nephrine before rHuEPO, and the subsequent increase in respon-
siveness with partial correction of the anemia by rHuEPO. It may
also explain the higher standing blood pressures that have been
reported when the associated anemia of primary autonomic
failure is treated with rHuEPO [39, 40]. The absence of a
correlation between vasoconstriction to norepinephrine and ei-
ther total peripheral resistance or arterial pressure in our study
suggests that enhanced adrenergic responsiveness may not fully
account for the pressor effects of rHuEPO. On the basis of
sympathetic microneurography, nerve activity does not appear to
contribute because, although basally increased in hemodialysis
patients, it is not further enhanced by rHuEPO [411.
In contrast with the responses to norepinephrine, the vascular
responsiveness to endothelin-1 tended to decrease rather than
increase with rHuEPO therapy. With some variability within the
data, the lack of statistical significance may reflect a type II
statistical error; indeed, the responsiveness to endothelin-1 did
decrease significantly when analyzed after exclusion of the patient
who had uncontrolled hypertension requiring a substantial change
in treatment during the study. Endothelin-1 induced vasoconstric-
tion correlated significantly but negatively with systolic arterial
pressure, mean arterial pressure and total peripheral resistance by
simple regression analysis, as has been observed previously in
normotensive but not hypertensive subjects [29]. This may have
several possible explanations. First, there may be a specific
reduction in responsiveness to endothelin-1 caused by an effect on
signal transduction mechanisms coupled to endothelin receptors,
but not to those for norepinephrine. This has been shown in the
blood vessels of hypertensive patients [42]. Second, there may be
true down-regulation of receptor expression. Third, there may be
decreased endothelin-1 receptor number owing to prior receptor
occupation by increased local concentrations of endothelin. This
might be expected if increased endothelin-1 production occurs.
Increased local production of endothelin-1 in response to
rHuEPO could account for the decreased blood vessel respon-
siveness to exogenous endothelin, while still being a factor in
causing the increase in arterial pressure and total peripheral
resistance. Conversely, increased systolic arterial pressure may
itself cause down-regulation of the endothelin receptor such as
has been described in some animal models [43, 44]. Such receptor
down-regulation would yield similar responses to exogenous en-
dothelin, but would occur as a result of changes in arterial
pressure and not as a cause. Further studies, using local infusion of
endothelin receptor antagonists, may serve to differentiate between
receptor down-regulation and increased receptor occupancy.
Although plasma endothelin concentrations were elevated in
our patients, they did not increase further following rHuEPO, in
contrast with some other studies [12, 17, 21]. This may have been
because rHuEPO was given subcutaneously and did not achieve
the same maximum plasma concentrations as when given by the
intravenous route [45]. Experimental evidence that rHuEPO
induces an increase in endothelin-1 production has usually re-
quired plasma concentrations of rHuEPO similar to those found
with intravenous rather than subcutaneous administration [36,
51. However, because 80% of endothelin-1 derived from the
vascular endothelial cell is released towards the vascular smooth
muscle [46], an unaltered plasma concentration of endothelin with
rHuEPO treatment does not exclude increased local vascular
production [471. Increased generation of endothelin-1 might
contribute to the increasing vascular responsiveness to norepi-
nephrine because low concentrations of endothelin-1 have been
shown in organ bath experiments to potentiate contractions to
norepinephrine [48].
Plasma endothelin did not correlate with the increase in
hemoglobin, arterial pressure or total peripheral resistance, but
did correlate with plasma urea, creatininc and the number of
hours dialyzed per week. These associations are probably multi-
factorial in origin, involving such variables as protein and carbo-
hydrate intake, body mass, the catabolic/anabolic state and clear-
ance of urea and creatinine by dialysis. How these indices of
protein metabolism relate to the concentration of endothelin-1 is
at present unclear.
In conclusion, this study has demonstrated that rHuEPO in-
creases blood pressure, and corrects the anemia and the impaired
vascular responsiveness to norepinephrine, in hemodialysis pa-
tients. In contrast, there was a trend for responsiveness to
endothelin-1 to be reduced by rHuEPO, and responsiveness to
endothelin-1 correlated inversely with the changes in arterial
pressure. The mechanisms underlying the changes in vascular
responsiveness to norepinephrine and endothelin- 1 with rHuEPO
treatment merit further investigation in studies using selective
antagonists at adrenergic and endotheliri receptors [23].
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